<DOC>
	<DOCNO>NCT00473213</DOCNO>
	<brief_summary>BetaferonR effective reduce relapse rate MRI T2-weighted lesion frequency MS patient dose 8 MIU alternate day ( THE IFNB MS Study Group , 1993 ) . Relapse rate reduce 30-35 % ( The IFNB MS Study Group , 1993 ) , MRI activity decrease 100 % case ( Stone et al 1995 ) . In patient , however , MRI activity still occur reappears treatment ( Stone et al 1995 ) . MRI activity demonstrate correlate relapse occurrence ( McFarland et al , 1992 ; Miller et al , 1996 ) , patient relapse still occur IFN beta treatment . In patient relapse may occur association appearance , 9-18 month treatment , anti-IFN beta NAB ( The IFNB M S Study Group , 1995 ) . This protocol hypothesize dose 12 MIU BetaferonR alternate day pronounce MRI clinical effect MS patient 8 MIU . MS patient respond 8 MIU may take advantage high dose . We , therefore decide assess MRI effect increase Betaferon dose ( 12 MIU ) RRMS patient show residual MRI activity ( least one new Gd enhance lesion ) six month standard Betaferon dose treatment ( 8 MIU ) .</brief_summary>
	<brief_title>Optimizing IFN Beta - 1B Dose</brief_title>
	<detailed_description>Comparing frequency new Gd enhance lesion group patient present residual MRI activity last four month six month standard dose ( 8MIU ) Betaferon treatment randomize continue standard dose increase dose 12 MIU Betaferon</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>1 . Written inform consent obtain . 2 . Age 18 50 year inclusive . 3 . Male female patient . 4 . Clinically definite laboratory support definite RR MS ( Poser et al , 1983 ) less 2 year . 5 . Two clinically documented relapse precede 24 month . 6 . No relapse relapse related neurological deterioration least 30 day prior entry study . 7 . Patients EDSS score 1 3.5 ( probably extend 5.5 ) . 8 . MRI activity . At least one enhance lesion baseline MRI runin study . 9 . Women capable child must agree use adequate contraceptive method ( condom spermicide , IUCD , oral contraceptive adequate barrier contraception ) . 10 . Caregivers agreement assist patient comply study requirement , necessary ( e.g . study drug administration , visit center ) . 1 . Any form Multiple Sclerosis relapsingremitting . 2 . Any disease could better explain patient 's sign symptom . 3 . Any disabling condition , could interfere clinical evaluation . 4 . Pregnancy lactation . 5 . Medical psychiatric , condition compromise patient 's ability give inform consent , comply trial protocol , complete study . 6 . Alcohol drug abuse 90 day precede screen visit . 7 . Uncontrolled clinically significant heart disease , i.e. , cardiac arrhythmia , uncontrolled angina pectoris , uncompensated congestive heart failure 8 . Clinically significant liver , renal bone marrow dysfunction define range laboratory evaluation . The following range ( see table 1 ) key laboratory evaluation consider adequate inclusion :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Interferon</keyword>
	<keyword>Magnetic Resonance</keyword>
</DOC>